Case Report
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 234-243
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.234
Figure 2
Figure 2 Disease progression after second-line treatment. 5-FU: 5-fluorouracil; Ad: Adrenal; B: Bevacizumab; Bo: Bone; C: Cetuximab; CAP: Capecitabine; CAPOX: Capecitabine + oxaliplatin; CNS: Central nervous system; ctDNA: Circulating DNA; DN: De novo disease; FOLFIRI: Folinic acid + fluorouracil + irinotecan; FOLFOX: Folinic acid + fluorouracil, and oxaliplatin; IRI: Irinotecan; Liv: Liver; Loc: Local; LN: Lymph node; Lun: Lung; Oxali: Oxaliplatin; Pat: Patient; Pt: Peritoneal; RASmut: RAS mutated; RASwt: RAS wild-type; RD: Relapsing disease; Rt: Rectum.